{"organizations": [], "uuid": "3b912a7ef28b56c2c34a7661907b67c487142519", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/legal", "section_title": "Legal News | Reuters", "url": "https://www.reuters.com/article/health-pfizer/supreme-court-declines-to-review-pay-for-delay-ruling-idUSL2N1QA1WZ", "country": "US", "domain_rank": 408, "title": "Supreme Court declines to review pay-for-delay ruling", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.001, "site_type": "news", "published": "2018-02-21T07:00:00.000+02:00", "replies_count": 0, "uuid": "3b912a7ef28b56c2c34a7661907b67c487142519"}, "author": "Nate Raymond", "url": "https://www.reuters.com/article/health-pfizer/supreme-court-declines-to-review-pay-for-delay-ruling-idUSL2N1QA1WZ", "ord_in_thread": 0, "title": "Supreme Court declines to review pay-for-delay ruling", "locations": [], "entities": {"persons": [], "locations": [{"name": "philadelphia", "sentiment": "none"}], "organizations": [{"name": "supreme court", "sentiment": "negative"}, {"name": "u.s. supreme court", "sentiment": "negative"}, {"name": "pfizer", "sentiment": "none"}, {"name": "3rd u.s. circuit court of appeals", "sentiment": "none"}, {"name": "ranbaxy inc", "sentiment": "none"}, {"name": "pfizer inc", "sentiment": "none"}, {"name": "teva pharmaceutical industries ltd", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "The U.S. Supreme Court on Tuesday declined to review a ruling that allowed class action lawsuits to proceed claiming Pfizer Inc and other companies entered into illegal deals to delay the availability of generic versions of Lipitor and Effexor XR.\nPfizer, Teva Pharmaceutical Industries Ltd and Ranbaxy Inc had petitioned the justices to review an August ruling by the 3rd U.S. Circuit Court of Appeals in Philadelphia that allowed purchasers of the drugs to pursue antitrust claims.\nTo read the full story on WestlawNext Practitioner Insights, click here: bit.ly/2EWmYEG\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html", "http://bit.ly/2EWmYEG"], "published": "2018-02-21T07:00:00.000+02:00", "crawled": "2018-02-21T06:25:41.015+02:00", "highlightTitle": ""}